De novo design and optimization of Aurora A kinase inhibitors

Tiago Rodrigues, Filip Roudnicky, Christian P. Koch, Takayuki Kudoh, Daniel Reker, Michael Detmar, Gisbert Schneider

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Drug discovery programs urgently seek new chemical entities that meet the needs of a demanding pharmaceutical industry. Consequently, de novo ligand design is currently re-emerging as a novelty-generating approach. Using ligand-based de novo design software, we computationally generated, chemically synthesized and biochemically tested a new arylsulfonamide against Aurora A kinase, a validated drug target in several types of cancer. The designed compound exhibited desired direct inhibitory activity against Aurora A kinase. By chemical optimization we obtained a lead structure exhibiting sustained activity in phenotypic assays. These results emphasize the potential of ligand-based de novo design to consistently deliver functional new chemotypes within short timeframes and limited effort.

Original languageEnglish
Pages (from-to)1229-1233
Number of pages5
JournalChemical Science
Volume4
Issue number3
DOIs
Publication statusPublished - Mar 2013

Fingerprint

Aurora Kinase A
Ligands
Software design
Pharmaceutical Preparations
Assays
Industry

ASJC Scopus subject areas

  • Chemistry(all)

Cite this

Rodrigues, T., Roudnicky, F., Koch, C. P., Kudoh, T., Reker, D., Detmar, M., & Schneider, G. (2013). De novo design and optimization of Aurora A kinase inhibitors. Chemical Science, 4(3), 1229-1233. https://doi.org/10.1039/c2sc21842a

De novo design and optimization of Aurora A kinase inhibitors. / Rodrigues, Tiago; Roudnicky, Filip; Koch, Christian P.; Kudoh, Takayuki; Reker, Daniel; Detmar, Michael; Schneider, Gisbert.

In: Chemical Science, Vol. 4, No. 3, 03.2013, p. 1229-1233.

Research output: Contribution to journalArticle

Rodrigues, T, Roudnicky, F, Koch, CP, Kudoh, T, Reker, D, Detmar, M & Schneider, G 2013, 'De novo design and optimization of Aurora A kinase inhibitors', Chemical Science, vol. 4, no. 3, pp. 1229-1233. https://doi.org/10.1039/c2sc21842a
Rodrigues T, Roudnicky F, Koch CP, Kudoh T, Reker D, Detmar M et al. De novo design and optimization of Aurora A kinase inhibitors. Chemical Science. 2013 Mar;4(3):1229-1233. https://doi.org/10.1039/c2sc21842a
Rodrigues, Tiago ; Roudnicky, Filip ; Koch, Christian P. ; Kudoh, Takayuki ; Reker, Daniel ; Detmar, Michael ; Schneider, Gisbert. / De novo design and optimization of Aurora A kinase inhibitors. In: Chemical Science. 2013 ; Vol. 4, No. 3. pp. 1229-1233.
@article{d0ff1d18f3b641589de044595943ae22,
title = "De novo design and optimization of Aurora A kinase inhibitors",
abstract = "Drug discovery programs urgently seek new chemical entities that meet the needs of a demanding pharmaceutical industry. Consequently, de novo ligand design is currently re-emerging as a novelty-generating approach. Using ligand-based de novo design software, we computationally generated, chemically synthesized and biochemically tested a new arylsulfonamide against Aurora A kinase, a validated drug target in several types of cancer. The designed compound exhibited desired direct inhibitory activity against Aurora A kinase. By chemical optimization we obtained a lead structure exhibiting sustained activity in phenotypic assays. These results emphasize the potential of ligand-based de novo design to consistently deliver functional new chemotypes within short timeframes and limited effort.",
author = "Tiago Rodrigues and Filip Roudnicky and Koch, {Christian P.} and Takayuki Kudoh and Daniel Reker and Michael Detmar and Gisbert Schneider",
year = "2013",
month = "3",
doi = "10.1039/c2sc21842a",
language = "English",
volume = "4",
pages = "1229--1233",
journal = "Chemical Science",
issn = "2041-6520",
publisher = "Royal Society of Chemistry",
number = "3",

}

TY - JOUR

T1 - De novo design and optimization of Aurora A kinase inhibitors

AU - Rodrigues, Tiago

AU - Roudnicky, Filip

AU - Koch, Christian P.

AU - Kudoh, Takayuki

AU - Reker, Daniel

AU - Detmar, Michael

AU - Schneider, Gisbert

PY - 2013/3

Y1 - 2013/3

N2 - Drug discovery programs urgently seek new chemical entities that meet the needs of a demanding pharmaceutical industry. Consequently, de novo ligand design is currently re-emerging as a novelty-generating approach. Using ligand-based de novo design software, we computationally generated, chemically synthesized and biochemically tested a new arylsulfonamide against Aurora A kinase, a validated drug target in several types of cancer. The designed compound exhibited desired direct inhibitory activity against Aurora A kinase. By chemical optimization we obtained a lead structure exhibiting sustained activity in phenotypic assays. These results emphasize the potential of ligand-based de novo design to consistently deliver functional new chemotypes within short timeframes and limited effort.

AB - Drug discovery programs urgently seek new chemical entities that meet the needs of a demanding pharmaceutical industry. Consequently, de novo ligand design is currently re-emerging as a novelty-generating approach. Using ligand-based de novo design software, we computationally generated, chemically synthesized and biochemically tested a new arylsulfonamide against Aurora A kinase, a validated drug target in several types of cancer. The designed compound exhibited desired direct inhibitory activity against Aurora A kinase. By chemical optimization we obtained a lead structure exhibiting sustained activity in phenotypic assays. These results emphasize the potential of ligand-based de novo design to consistently deliver functional new chemotypes within short timeframes and limited effort.

UR - http://www.scopus.com/inward/record.url?scp=84876736732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876736732&partnerID=8YFLogxK

U2 - 10.1039/c2sc21842a

DO - 10.1039/c2sc21842a

M3 - Article

VL - 4

SP - 1229

EP - 1233

JO - Chemical Science

JF - Chemical Science

SN - 2041-6520

IS - 3

ER -